Kraig Biocraft Laboratories to Launch Commercial Production of Monster Silk(TM)
July 15 2013 - 6:05AM
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the
leading developer of advanced spider silk based fibers, today
announced that it is scheduled to start commercial production of
Monster Silk™.
The first phase, scheduled to begin within the next three weeks,
will be focused on establishing commercial scale production
capacity. "We have been laying the ground work for commercial
production over the last six months with our pilot production
program," said Company CEO and founder, Kim K Thompson. "We
have moved cautiously and prudently in testing our methods and
procedures. It's now time to convert the pilot program to
commercial production."
The launch of commercial production follows on the heels of the
Company's pilot production program which has been running since
January.
"The successful scale-up to commercial production is a
significant milestone for any company," continued Thompson, "and,
considering the importance we place on Monster Silk™, I have to
agree that this is a momentous step for Kraig. It is
especially exciting because we are creating what we believe will be
the world's first commercial scale production of recombinant spider
silk."
While the Company is creating this production capacity, it is in
discussions with one or more other countries about further
expanding and diversifying its production capacity for Monster
Silk™.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully
reporting biotechnology company is the leading developer of
genetically engineered spider silk based fiber technologies. The
Company has achieved a series of scientific breakthroughs in the
area of spider silk technology with implications for the global
textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and
expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's
current views and assumptions. As a result, there can be no
assurance that management's expectations will necessarily come to
pass. These forward-looking statements generally can be identified
by phrases such as "believes," "plans," "expects," "anticipates,"
"foresees," "estimated," "hopes," "if," "develops," "researching,"
"research," "pilot," "potential," "could" or other words or phrases
of similar import. Forward looking statements include descriptions
of the Company's business strategy, outlook, objectives, plans,
intentions and goals. All such forward-looking statements are
subject to certain risks and uncertainties that could cause actual
results to differ materially from those in forward-looking
statements.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From Apr 2024 to May 2024
Kraig Biocraft Laborator... (QB) (USOTC:KBLB)
Historical Stock Chart
From May 2023 to May 2024